For the quarter ending 2025-09-30, CTSO made $9,485,000 in revenue. -$3,170,000 in net income. Net profit margin of -33.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 9,485,000 | 9,617,000 | 8,727,238 | 8,154,748 |
| Cost of goods sold | 2,819,000 | 2,803,000 | 2,519,641 | 1,483,924.5 |
| Gross profit | 6,666,000 | 6,814,000 | 6,207,597 | 6,670,823.5 |
| Research and development, net of grant income | 918,000 | 1,262,000 | 1,662,925 | 1,729,045.25 |
| Selling, general and administrative | 8,610,000 | 9,167,000 | 8,431,880 | 9,427,213.25 |
| Total operating expenses | 9,528,000 | 10,429,000 | 10,094,805 | 11,156,258.5 |
| Loss from operations | -2,862,000 | -3,615,000 | -3,887,208 | -4,485,435 |
| Interest expense, net | -645,000 | -616,000 | -605,134 | -315,420.5 |
| Gain (loss) on foreign currency transactions | -64,000 | 6,178,000 | 3,013,984 | -3,165,402 |
| Miscellaneous income (expense) | - | - | - | -7.5 |
| Total other income (expense), net | -709,000 | 5,562,000 | 2,408,850 | -3,480,837.5 |
| Loss before benefit from income taxes | -3,571,000 | - | -1,478,358 | -7,966,272.5 |
| Benefit from income taxes | -401,000 | - | - | 1,941,120.75 |
| Net loss | -3,170,000 | 1,947,000 | -1,478,358 | -5,179,739.25 |
| Earnings per share, basic | -0.05 | 0.03 | -0.02 | -0.13 |
| Earnings per share, diluted | -0.05 | 0.03 | -0.02 | -0.13 |
| Weighted average number of shares outstanding, basic | 62,753,959 | 62,608,598 | 60,731,929 | -27,162,219 |
| Weighted average number of shares outstanding, diluted | 62,753,959 | 67,166,377 | 60,731,929 | -27,162,219 |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)